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INFOLEHT 
Transcriptome profile of extracellular vesicles derived from the synovial fluid and blood 
of osteoarthritis patients 
Osteoarthritis (OA) is a chronic, musculoskeletal disease that affects quite a sizeable portion 
of the older generation. Late-stage OA has a considerable negative impact on the quality of 
life; however, it is very difficult to diagnose OA in the early stages. Therefore, there is a need 
to find new non-invasive diagnostic methods for early disease detection. Extracellular vesicles 
(EVs) are capable of protecting their RNA cargo during transportation and for this reason, 
there is a growing interest in EV-RNAs as potential biomarkers for different diseases and 
conditions. miRNAs have been shown to be dysregulated in the synovial fluid (SF) of OA 
patients and have been presented as potential biomarkers. miRNAs such as miR-146a and 
miR-26b have been shown to play a potential role in OA pathogenesis and have also been 
found to be significantly dysregulated in OA-SF. However, as there is a lack of research done 
on blood-EVs, further experiments need to be done in order to determine if the SF-EV profile 
reflects in blood-EVs.  
Keywords: extracellular vesicles; osteoarthritis; miRNA; blood; synovial fluid. 
CERCS: B220 Genetics, cytogenetics 
Ekstratsellulaarsete vesiikulite transkriptoomiline profiil osteoartriiti põdevate 
patsientide sünoviaalvedelikus ja veres 
Osteoartriit (OA) on krooniline luu- ja lihakonna haigus, mis mõjutab üsna suurt osa 
vanemaealisest elanikkonnast. OA-d on raske varajases staadiumis diagnoosida mistõttu 
otsitakse lahendusi, kuidas mitteinvasiivselt diagnoosida varajases staadiumis OA-d ning selle 
kaudu parandada OA põdevate patsientide elukvaliteeti. Ekstratsellulaarsed vesiikulid (EV-d) 
on võimelised RNA-d kaitsma transpordi ajal ning selletõttu EV-de RNA-d pakuvad huvi kui 
biomarkerid diagnostikas. miRNA-d on näidatud, et OA patsientide sünoviaalvedelikus (SF) 
on nende ekspressioonimuster muutnud ja seetõttu võiks need olla potentsiaalseks 
biomarkeriteks. miRNA-d nagu miR-146a ja miR-26b võtavad osa OA progressioonis ning on 
leitud, et need on oluliselt dereguleeritud nii OA-SF kui ka OA-SF EV-des. Veres olevaid 
EV-sid on vähe uuritud mistõttu on vaja täiendavaid katseid, et teha kindlaks, kas nende 
profiil kajastub vere EV-des. 
Märksõnad: ekstratsellulaarsed vesiikulid; osteoartriit; miRNA; veri; sünoviaalvedelik 
CERCS: B220 Geneetika, tsütogeneetika  
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ABBREVIATIONS 
ABs  apoptotic bodies 
ACD dextrose 
AFSCs amniotic fluid stem cells 
AMPK AMP-activated protein kinase 
BMDCs bone marrow-derived dendritic cells 
BMSC bone marrow stromal/stem cell derived extracellular vesicles 
COL2A1 collagen type II alpha 1 chain 
DEGs differentially expressed genes 
DGUC iodixanol density gradient ultracentrifugation 
DUG differential ultracentrifugation 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
ESCRT endosomal sorting complex required for transport 
EVs extracellular vesicles 
exRNA extracellular RNA 
GPIb glycoprotein Ib 
HA hyaluronic acid 
HSNPs hollow silica nanoparticles 
IFNs interferons 
KPNA karyopherin subunit alpha 
MAPK  mitogen-activated protein kinase 
MMP matrix metallopeptidase 
MSCs mesenchymal stem cells 
MVs microvesicles 
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MVEs multivesicular endosomes 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
NGS next generation sequencing 
NTA nanoparticle tracking analysis 
OA osteoarthritis 
RA rheumatoid arthritis 
PBMCs peripheral blood mononuclear cells 
PG prostglandin 
PPAR peroxisome proliferator-activated receptors 
PSPMA poly(3)-sulfopropyl methacrylate potassium 
PTGS2 prostaglandin-endoperoxide synthase 2 
RBCs  red blood cells 
SDGUC sucrose density gradient ultracentrifugation 
SEC  size exclusion chromatography  
SEVs Staphylococcus aureus extracellular vesicles 
SF synovial fluid 
TGB-β transforming growth factor beta 
TEM transmission electron microscopy 
TEx tumour-derived exosomes 
TLR toll-like receptor 
TMv tumour-derived microvesicles 
TSG101 tumour susceptibility gene 101  
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INTRODUCTION 
Osteoarthritis (OA) is a disease that affects a significant part of the older population. 
Although there is no cure for OA, it is possible to manage the symptoms and if the symptoms 
are not manageable anymore, then endoprosthesis is done on severely damaged joints for 
patients with end-stage OA. For this reason, there is an interest in trying to find a biomarker 
for the disease through which it would be possible to diagnose OA in the early stages, and, 
through this, improve a patients’ quality of life by slowing down the progression of OA. 
However, currently there are no good biomarkers to diagnose early OA prior to the 
appearance of radiological findings. 
One possible way to detect OA biomarkers is by analysing the synovial fluid (SF) of OA 
patients, however, it is not the best diagnostic method. SF samples are obtained from patients 
through joint aspiration which is an invasive method and generally conducted only prior to 
joint arthroplastic surgery. The SF is not used for diagnostic purpose and for research, only 
perioperatives samples are often available. Therefore, even if the SF does contain possible 
biomarkers for the disease, it is not a preferred diagnostic method. On the other hand, 
obtaining and analysing patients’ blood samples is much more efficient and plausible. A 
proposed method for OA diagnosis is through the analysis of extracellular vesicles (EVs) as 
both the SF and blood contain EVs.  
EVs are vesicles that are involved in cell-to-cell communication and transport of different 
molecules. Many studies have already demonstrated their possible role in OA pathogenesis as 
well as their possible use in OA therapeutics as the function of these vesicles seems to depend 
on the cell they are derived from . EVs contain different molecules including RNA and are 
capable of safely transporting them due to their phospholipid bilayer that protects their cargo 
from degradation.  
The general aim of this study is to give an overview of the current knowledge regarding the 
general transcriptomic profile of OA and, more specifically, the transcriptomic profile of SF 
and blood EVs. I hope to achieve this by first giving a general overview of the transcriptomic 
profile of OA and then introducing several OA studies regarding EVs derived from tissues, 
specifically SF and blood. I will analyse the role of the detected RNA in SF and plasma 
derived EVs and evaluate the potential of applying EVs as biomarkers to diagnose OA. 
This study was carried out at the Institute of Bio- and Translational Medicine. 
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1. LITERATURE OVERVIEW 
1.1. Blood components 
Human blood is composed of 78% water and 22% solids. Red blood cells (erythrocytes), 
white blood cells (leukocytes) and platelets (thrombocytes) make up the solid part of the 
blood (Ameta et al., 2017). Red blood cells are flexible and have an oval biconcave shape. 
Mature red blood cells have no nucleus and are missing most organelles to accommodate 
haemoglobin which makes up about 96% of red blood cells dry content (by weight), and 35% 
of total content including water. Haemoglobin transports oxygen from the lungs around the 
human body  (C.-L. Wang et al., 2017). White blood cells are very important in both the 
innate and adaptive immune system and there are approximately 4,000 to 10,000 white blood 
cells per microlitre of blood in an adult human body. They can be separated into four 
subclasses: eosinophils, lymphocytes, monocytes and neutrophils (Togacar et al., 2019). 
Platelets are fragments of cytoplasm, derived from megakaryocytes that do not have a nucleus 
and have a lifespan of eight to ten days. They participate in different physiological responses 
such as homeostasis, thrombosis, wound healing and immunity. 150-450 billion platelets 
circulate in the human body per litre of blood and a turnover of 100 billion platelets occurs 
daily to maintain a physiological platelet concentration (Lefrançais and Looney, 2019). Figure 
1 shows the ontogeny of the different types of blood cells mentioned above. 
 
Figure 1. Distribution and origin of various blood components (NCI Dictionary of Cancer 
Terms, 2011). 
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Blood plasma is a protein-rich solution in which red and white blood cells as well as platelets 
are suspended (Leeman et al., 2018). It is the pale yellow liquid fraction of blood that makes 
up approximately 55% of the body’s total blood volume (C.-L. Wang et al., 2017). Blood 
serum is differentiated from blood plasma by the absence of fibrinogens and clotting factors 
(Leeman et al., 2018).  
1.2. Synovial Fluid 
Synovial joints, such as the wrist, knee, ankle, shoulder, and hip joints, are freely moveable 
joints that allow for a wide range of motions. In a healthy synovial joint (Figure 2), ends of 
the bones are covered with a smooth (hyaline) cartilage layer which functions as a shock 
absorber and forms a gliding surface (Tamer, 2013). Synovial joints are surrounded by the 
joint capsule, which has an external dense fibrous layer and an internal synovial membrane 
(synovium). The synovium contains macrophage-like synoviocytes (Type A) and fibroblast-
like synoviocytes (Type B). Type A synoviocytes are located within the superficial layer of 
the synovium whereas type B synoviocytes lie in the deeper layer and secrete hyaluronic acid 
(HA) and collagens into the synovial fluid (SF) (Ando et al., 2010). The SF is an ultra-filtrate 
of blood plasma filtrated through the synovial membrane and it functions as a biological 
lubricant while also containing nutrients and regulatory cytokines. Molecules that are said to 
play a role in lubrication of the joint, either alone or together, are proteoglycan 4, HA and 
surface-active phospholipids, all of which are secreted from synoviocytes. Within the joint, 
HA protects the cartilage and transports nutrients to the avascular cartilage (Tamer, 2013). 
 
Figure 2. Structure and components of a healthy synovial joint. (Tamer, 2013) 
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1.3.  Transcriptomics 
Transcriptomics is the study of a cell’s transcriptome which is all of the RNA transcripts 
found within a cell (Lowe et al., 2017;Pertea, 2012). mRNA is a protein-coding RNA 
molecule while the rest of the RNA molecules present in a cell are non-coding. Ribosomal 
RNA (rRNA) and X-inactive specific transcript RNA (XIST RNA) are long non-coding RNA 
molecules (lncRNA) while microRNA (miRNA), small interfering RNA (siRNA), repeat 
associated small interfering RNA (rasiRNA), small nucleolar RNA (snoRNA), small nuclear 
RNA (snRNA), piwi-interacting RNA (piRNA), Y RNA and vault associated RNA (vtRNA), 
to name a few, are small non-coding RNAs (ncRNA). All these RNA molecules and their 
main functions are listed in Table 1.  
Table 1. Summary of RNA molecules and their functions. (Dogini et al., 2014; Gerstberger et 
al., 2014) 
RNA molecule Function 
messenger RNA (mRNA) Contains the codons in a specific order from which 
proteins are synthesized. 
transfer RNA (tRNA) Transports amino acids to the ribosome to form a 
protein chain 
ribosomal RNA (rRNA) Protein synthesis 
X-inactive specific transcript RNA 
(XIST RNA) 
Inactivates the X chromosome 
microRNAs (miRNA) Help to regulate post-transcriptional gene expression 
small interfering RNAs (siRNA) Take part in gene regulation and help in the defence 
against virus and transposon activity 
repeat associated small interfering 
RNAs (rasiRNA) 
Take part in the formation of the centromere 
small nucleolar RNAs (snoRNA) Participate in the modification and processing of 
rRNA 
small nuclear RNAs (snRNA) Involved in the spliceosome complex 
piwi-interacting RNAs (piRNA) Regulate transposon activity 
Y RNA Acts as RNA chaperons, participates in DNA 
replication and in the immune response 
vault associated RNAs (vtRNA) Part of the vault ribonucleoprotein (RNP) complex 
and down regulates mRNA targets 
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1.4.  Nature, origin and function of extracellular vesicles 
Extracellular vesicles (EVs) have been found in archaea, bacteria and eukaryotes (Armstrong 
and Wildman, 2018) and they been found in all body fluids hinting towards their 
physiological importance (Dickhout and Koenen, 2018). They can be detected in blood 
plasma and serum, urine, saliva, amniotic fluid and breast milk (Kalra et al., 2012) as well as 
synovial fluid (Miyaki and Lotz, 2018). EVs can also be found in semen, bronchial fluid, 
cerebral spinal fluid, tears, bile, gastric acid (Doyle and Wang, 2019), liver, brain, and 
placenta (Panteleev et al., 2017). Hematopoietic cells such as B lymphocytes, dendritic cells, 
T lymphocytes and mast cells secrete EVs as well as non-hematopoietic cells such as 
intestinal epithelial cells, neuroglial cells and tumour cells. Platelets have also been shown to 
release EVs (Caby et al., 2005).  
EVs are membrane enclosed vesicles that used to be regarded as inert cellular debris released 
as a result of cell damage or dynamic plasma membrane turnover (Miyaki and Lotz, 2018). It 
has since been proven that EVs play an important role in cell-to-cell signalling in both normal 
physiological processes as well as pathological progression (Abels and Breakefield, 2016). 
EVs influence recipient cell function through the transferral of information. These signals can 
be transmitted by biomolecules such as proteins, lipids, nucleic acids and sugars (Yáñez-Mó et 
al., 2015). EVs also have a phospholipid bilayer that protects the nucleic acids from 
degradation (H. Wang et al., 2019). 
Due to their mode of biogenesis, EVs have been divided into three subgroups: exosomes, 
ectosomes (also referred to as microvesicles), and apoptotic bodies (Kalra et al., 2012) as 
described in Figure 3. 
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Figure 3. Rough size range of extracellular vesicles and a comparison to other molecules. 
(György et al., 2011) 
1.4.1. Exosomes 
Exosomes are typically 30-100 nm in diameter (van Niel et al., 2018). They are formed by the 
inward budding of the endosomal membrane during the maturation of multivesicular 
endosomes (MVEs) and are secreted once the MVEs fuse with the plasma membrane (van 
Niel et al., 2018) as shown in Figure 4 (p.13). Endosomes are divided into three subtypes; 
early, late and recycling. Early endosomes that fuse with endocytic vesicles are destined for 
degradation, recycling or secretion. Remaining endosomes transform into late endosomes 
during which cytosolic bodies, nucleic acids, and lipids are sorted into small vesicles. Late 
endosomes containing these vesicles are named MVEs. MVEs that fuse with the lysosome are 
fated for degradation but if they fuse with the cellular membrane, then they are released as 
exosomes (Abels and Breakefield, 2016). 
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Figure 4. Different modes of biogenesis of microvesicles, exosomes, and apoptotic bodies 
(Lawson, 2017).  
Exosomes released from parental cells have been shown to interact with target cells, 
influencing their behaviour and phenotype features. The genetic material of exosomes gets 
delivered via receptor-ligand interactions, direct fusion of membranes, or endocytosis (Y. 
Zhang et al., 2019). During migration, the integrity of exosomal cargo is protected (Joo et al., 
2020) as demonstrated by RNA cargo remaining intact and resistant to RNase activity during 
migration (Valadi et al., 2007). Exosomes are also capable of mediating intercellular 
communication throughout the body via the blood without inducing immune responses (Joo et 
al., 2020). However, in the immune system this exosome mediated intercellular 
communication has been shown to influence antigen presentation, immune activation, 
immune suppression, and immune tolerance demonstrating the function of exosomes in 
immunoregulation (Y. Zhang et al., 2019). Depending on their specific characteristics, 
exosome can be used in disease diagnosis, for drug delivery, and as therapeutic agents (Joo et 
al., 2020). 
1.4.2. Microvesicles 
Microvesicles (MVs) are also known as shedding vesicles, ectosomes, shedding bodies, and 
microparticles (Tricarico et al., 2016). The size of a normal vesicle ranges from 50 to 1000 
nm but, in the case of oncosomes (MVs released from cancer cells), they can also be as big as 
10 μm (van Niel et al., 2018). MVs are shed from activated or apoptotic cells (Ridger et al., 
2017). When shed from normal cells, the rate of release is slow but MVs are released from 
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tumours at a constant rate (György et al., 2011). The formation of MVs is caused by the 
redistribution of phospholipids and the contraction of the actin-myosin machinery. ADP-
ribosylation factor 6 causes a cascade that activates phospholipase D. This leads to the 
phosphorylation of the extracellular signal-regulated kinase on the plasma membrane 
activating the myosin light chain kinase which is followed by the outward budding and fission 
of the plasma membrane resulting in the release of MVs into the extracellular space (Abels 
and Breakefield, 2016) as shown in Figure 4 (p.13). 
MVs have been shown to have a variety of functions including playing a role in cell-to-cell 
communication (van Niel et al., 2018) and having procoagulant activity (György et al., 2011). 
As well as this, MVs have also been shown to cause a pro-inflammatory response when 
interacting with naïve endothelial cells (Ridger et al., 2017), secreting IL-1β, contributing to 
the proinvasive nature of tumours, oncogenic cellular transformation and participating in feto-
maternal communication (György et al., 2011). 
1.4.3. Apoptotic bodies 
Apoptotic bodies (ABs) are also referred to as apoptotic cell-derived microparticles and 
apoptotic blebs. ABs are produced when the nuclear and cytoplasmic components are packed 
into membrane-bound vesicles during cell disassembly (Hauser et al., 2017) and are released 
as blebs from cells undergoing apoptosis (György et al., 2011) as shown in Figure 4 (p.13). 
They are about 1 - 5μm in diameter, roughly comparable to the size of platelets (Figure 3, 
p.12) but they can also be 50-500 nm in size (György et al., 2011). The presence of 
phosphatidylserine on the surface membrane as well as the presence of intact organelles 
within the vesicle are key characteristics of ABs (Akers et al., 2013). They also contain intact 
chromatin and small amounts of glycosylated proteins (Doyle and Wang, 2019). ABs may 
also include mRNAs, lncRNAs, rRNA, miRNAs, or fragments of intact RNA molecules (Zhu 
et al., 2017).  
The composition of apoptotic bodies varies; some are made of condensed nuclear chromatin 
while others are made of cytoplasmic components. This affects their physical properties 
which can affect how ABs are purified when the methods use density, gravity, or charge to 
separate them. This difference is due to tightly packed DNA being denser and it carries a 
negative charge. In addition to this, they are stained by different markers which is a result of 
ABs containing either DNA or cytoplasmic proteins. This led to ABs being divided into 
nuclear apoptotic bodies and cytoplasmic apoptotic bodies (Hauser et al., 2017). 
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ABs have been shown to take part in the horizontal transfer of oncogenes and DNA, yielding 
presentation of T cell epitopes upon uptake by phagocytic cells and representation of B cell 
autoantigens. Uptake of ABs has been shown to lead to immunosuppression (György et al., 
2011). Signals in apoptotic bodies attract phagocytes to apoptotic sites for apoptotic cell 
clearance (Hauser et al., 2017). Instead of isolating ABs, most studies use co-cultures of cells 
that are going through apoptosis to investigate their functions (György et al., 2011). 
1.4.4. Proteins, lipids and nucleic acids in EVs 
EV cargo reflects the intracellular origin of the cargo as well as they type of cell from which 
the vesicle was derived (Sedgwick and D’Souza‐Schorey, 2018). The most commonly found 
proteins in EVs are those that also participate in their biogenesis – this includes the proteins 
that are associated with the endosomal pathway (Abels and Breakefield, 2016). There have 
been reports of transcription factors contained in EVs (Kalra et al., 2012); however proteins 
associated with the endoplasmic reticulum, Golgi, and nucleus have not been found in smaller 
EVs such as exosomes and MVs (Abels and Breakefield, 2016). Exosomes are enriched in 
major histocompatibility complex class II molecules (MHCII) and tetraspanins CD37, CD53, 
CD63, CD81, and CD82. The endosomal sorting complex required for transport (ESCRT) is a 
group of proteins that are necessary in the formation of MVEs. This pathway also needs 
additional proteins such as Alix and tumour susceptibility gene 101 (TSG101). MVs, on the 
other hand, tend to be enriched in integrins, glycoprotein Ib (GPIb), and P-selectin. They also 
carry more proteins with posttranslational modifications like glycoproteins or 
phosphoproteins. Lastly, ABs contain DNA-binding histones and are depleted in 
glycoproteins. Proteins such as MHC II, tetraspanins, ESCRT proteins, Alix, TSG101, and 
heat-shock chaperone proteins can be used as general EV biomarkers (Zaborowski et al., 
2015). 
EVs are mainly enriched with small RNAs but DNA has also been found. Many of these 
RNAs are derived from ribosomal 18S and 28S rRNAs and tRNAs. RNA molecules found 
includes mRNAs, miRNAs, tRNAs, long and short non-coding RNAs, tRNA fragments, 
piRNAs, vtRNAs, and Y RNAs. Most of these molecules are 200 nucleotides long and most 
are also fragmented. Circular RNAs are also enriched and stable in EVs (Abels and 
Breakefield, 2016). About 15% of EV-RNA consists of miRNA and tRNAs and the amount 
of RNA molecules can vary as oncosomes contain more RNA molecules than EVs from 
normal cells (Zaborowski et al., 2015). 
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DNA transported by EVs is referred to as EV-DNA and its size varies from 100 bp to 2.5 kB. 
Long double stranded DNA fragments can also be found in EV pellets, but they are 
unprotected from DNase activity as they are not enclosed in the EV membrane. The 
functional significance of this cargo is unknown (Zaborowski et al., 2015). 
1.5. EVs in blood and synovial fluid 
1.5.1. EVs in blood 
Originally, EVs in blood plasma were named platelet dust and described as “subcellular 
materials originating from platelets in plasma and serum” (van Niel et al., 2018). Majority of 
the EVs that circulate in plasma are of platelet origin, but their mode of biogenesis is still 
unclear. EVs have also been found to originate from both erythrocytes and leukocytes as well 
(Panteleev et al., 2017).  
In addition to EVs, blood also contains soluble proteins and lipoproteins as a result of which 
blood plasma and serum have high viscosity and density. Due to this, it is hard to accurately 
detect, isolate and evaluate the concentration of EVs (Clayton et al., 2019), however, in spite 
of this, it has been calculated that there are approximately 5*109 EVs per mL of plasma in a 
healthy person’s blood (H. Wang et al., 2019). EVs isolated from the serum of healthy 
humans have been reported to activate endothelial cells as well as having proangiogenic 
functions in vitro and in vivo (Takov et al., 2018).  
EVs partake in coagulation and inflammation in blood while higher EV levels have been 
associated with cardiovascular diseases, cancer, sepsis, and autoimmune diseases (Arraud et 
al., 2014). As well as this, it has been shown that the number of EVs originating from 
erythrocytes increases in the case of sickle-cell anaemia, beta-thalassemia, and other diseases 
but normally, there are less EVs of erythrocytes origin than of platelet or leukocyte origin 
(Panteleev et al., 2017). 
1.5.2. EVs in synovial fluid 
EVs in SF have been shown to have pro-inflammatory properties (Foers et al., 2018) and to 
facilitate coagulation (Berckmans et al., 2002). As well as this, SF-EVs have been shown to 
play a role in the progression of OA (Domenis et al., 2017). 
Domenis et al. investigated the immune regulatory properties of OA SF-EVs on pro-
inflammatory M1 macrophages differentiated from peripheral blood mononuclear cells 
(PBMCs). Treatment of M1 macrophages with SF-derived exosomes resulted in the release of 
IL-1β and induced the released of chemokines CCL8, CCL15, CCL20, and CXCL1 while 
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downregulating the production of CCL7. There was also a release of MMP12 and MMP7 
while MMP8 production was inhibited (Domenis et al., 2017). IL-1β is one of the main 
proinflammatory cytokines involved in OA pathophysiology (Kapoor et al., 2011) while 
CCL8 and CCL7 are chemoattractants that recruit monocytes to sites of trauma and infection 
and, in the case of OA, to sites of inflammation (Yung and Farber, 2013). CCL20 induces 
changes in phenotype and catabolic gene expression in chondrocytes (Alaaeddine et al., 2015) 
while CXCL1 induces chondrocyte hypertrophy and apoptosis during cartilage development 
as well as playing a role in inflammation (Wenke et al., 2011). Increased MMP12 expression 
has been shown to be expressed in the cartilage and subchondral bone of OA patients but it 
was absent in normal controls (Kaspiris et al., 2015). MMP7 degrades various ECM 
components such as cartilage proteoglycans and it is overexpressed in OA (Y. Tao et al., 
2015). MMP8 causes hyperinfiltration of joints with neutrophils as it downregulates 
neutrophil apoptosis and clearance (Rose and Kooyman, 2016). 
1.5.3. Transcriptome of EVs in blood and SF 
More detailed studies of EVs in blood have been performed but an in-depth study of the OA-
EV transcriptomic profile is yet to be performed. Amorim et al. performed a whole 
transcriptomic analysis of EVs isolated from the plasma of 5 healthy women. They concluded 
that 73.25% of the reads were short non-coding RNAs, 24.46% were protein coding RNAs, 
2.16% long non-coding RNAs and 0.1% pseudogenes. In the short non-coding RNA category, 
57.29% were tRNAs, 14.83% were mitochondrial rRNAs, 13.23% were miscellaneous RNAs 
and 12.86% were miRNAs. Amongst the miscellaneous RNA category were Y RNAs 
(57.45%), SRP_7SL_RNAs (39.44%), vtRNAs (2.99%) and 7SK_RNAs (0.11%) (Amorim et 
al., 2017). 
Hunter et al. performed a more in-depth transcriptomic analysis of human plasma and PBMCs 
by focusing on the miRNA content within MVs. Results showed that 104 miRNAs in MVs 
and 75 miRNAs in PBMC samples were significantly expressed while 71 of these were co-
expressed among each sample. miR-223, -484, -191, -146a, -16, -26a, -222, -24, -126, and -32 
were detected in plasma microvesicles, while miR-222, -24, -126, and -32 were the top 
expressed. miR-150, -146b, -19b and -20a were among the highest miRNAs detected in 
PBMC, but not in plasma microvesicles. However, both samples contained miR-223, -484, -
191, -146a, -16, and -26a. miR-486 was the highest differentially expressed miRNA in the 
plasma MVs compared to PBMC. As many plasma MVs were platelet-derived, the miRNA 
expression of platelets was observed. There were 53 co-expressed miRNAs but there were 
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also many miRNAs unique to plasma MVs. miR-223 was the highest expressed miRNA in 
platelets but there was no observed expression of miR-484 in platelets. (M. P. Hunter et al., 
2008). 
While the general transcriptomic profile of EVs in blood has been investigated, the same 
cannot be said for the general transcriptomic profile of EVs in SF regarding OA. However, 
some have investigated the SF-EV miRNA profile in the case of diseases such as OA. Kolhe 
et al. discovered that the SF-EV profile could be gender specific as the only miRNA 
significantly expressed by both genders was miR-504. Overall, they found that 69 miRNAs 
were significantly down-regulated, and 45 miRNAs were up-regulated in males while in 
females, 91 miRNAs were down-regulated and 53 miRNAs up-regulated (Kolhe et al., 2017). 
Furthermore, Griswold et al. analysed the transcriptomic profile of SF extracellular RNA 
(exRNA) following knee trauma. They observed that the expression of 69 protein coding 
genes (44 up-regulated, 25 down-regulated) and eight miRNAs (3 up-regulated, five down-
regulated) showed significant differences, especially MMP3, MMP21, MMP1 and miR-320a 
(Griswold et al., 2018). 
However, comparing the transcriptomic profile of the SF and blood in this case is quite 
difficult. Mainly because the blood is not taken from OA patients but rather from healthy 
patients. Secondly, one study focuses on blood EVs, another on blood MVs and lastly, SF 
exosomes. As these studies are not based on similar EV subtypes, comparing them is not 
accurate and therefore not possible.  
1.6. Potential medical applications of EVs 
EVs present a unique opportunity for the development of a new class of therapeutics due to 
their wide range of biological functions and capability to shuttle large molecules between 
cells (Wiklander et al., 2019). Different types of EV molecules are being studied for 
numerous therapeutic applications. This includes the use of EVs in anti-tumour therapy, 
pathogen vaccination, immune-modulatory and regenerative therapies as well as drug delivery 
(Lener et al., 2015).  
1.6.1. EVs in anti-tumour therapy 
Tumour-derived EVs have tumour-specific integrins which directs them towards the tumour 
or metastatic sites.  Thus tumour-derived exosomes (TEx) and MVs (TMv) are ideal as 
carriers for therapeutic agents. The tumour microenvironment can be regulated by the delivery 
of inflammatory cytokines and by the elimination of suppressing factors. Rossowska et al. 
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focused on transforming growth factor beta (TGF-β1) and IL-12 (Rossowska et al., 2019). 
TGF-β1 is an anti-inflammatory cytokine associated with tumour progression and metastasis 
(Principe et al., 2014) while IL-12 is a proinflammatory cytokine that has high antitumour 
potential as well as high toxicity when applied in its recombinant form (Lasek et al., 2014). 
Rossowksa et al. developed and analysed TGF-β1-deprived EVs with IL-12 cargo and the 
results showed that TEx from unmodified MC38 cells accelerated tumour growth while 
modified TEx, especially those deprived of TGF-β1, caused tumour growth inhibition 
(Rossowska et al., 2019). 
1.6.2. EVs in pathogen vaccination 
EVs derived from gram-negative bacteria contains pathogenic components or virulence 
factors due to which they can be used as vaccination agents by inducing both innate and 
adaptive immunity. When bone marrow-derived dendritic cells (BMDCs) were treated with 
Staphylococcus aureus EVs (SEVs), they were discovered to have the vaccine adjuvant ability 
to induce adaptive immunity. The expression of co-stimulatory molecules was enhanced in 
BMDCs as were the production of pro-inflammatory mediators. The SEV vaccination was 
tested against S. aureus-induced pneumonia in a mouse model. CD4+ T cells were transferred 
from SEV-immunized mice to naïve mice of which 70% showed an effective protective 
response to the infection, demonstrating that the vaccination induced by SEV-immunization is 
mediated mainly by CD4+ cell responses (Choi et al., 2015). 
1.6.3. EVs in immunomodulatory therapies 
Mesenchymal stem cells (MSCs) are important in maintaining tissue homeostasis (Xiuxiu Yin 
et al., 2019) and have been isolated from bone marrow, adipose tissue, the skin, lungs and the 
umbilical cord (Kim et al., 2019). By releasing inflammatory cytokines into the tissue 
microenvironment (Trapani et al., 2016), MSCs have also been shown to participate in 
immunomodulatory effects in both acute and chronic diseases (Tan et al., 2019). It has been 
suggested that the immunomodulatory effect of MSCs comes from the secreted EVs rather 
than from the MSCs themselves. Depending on the cellular origin and cytokine cargo of EVs, 
they can either have an immune-stimulatory or immune-suppressive effects (Kordelas et al., 
2019). EVs partake in tissue repair and immune regulation due to their ability to mediate 
MSCs paracrine mechanism (Trapani et al., 2016). 
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1.6.4. EVs in regenerative therapies 
Amniotic fluid stem cells (AFSCs) have already been shown to have beneficial effects in 
organ and tissue regeneration. These regenerative studies have been carried out on the kidney, 
heart, intestine, lung, bone, bladder, and muscle. AFSCs beneficial effects have been 
attributed partially to EVs which mediate paracrine intercellular communication. Antounians 
et al. demonstrated the regenerative capabilities of AFSC-EVs by treating nitrofen damaged 
lung epithelium cells with AFSC-EVs resulting in a significant reduction in the rate of cell 
death. They also found that the effect of AFSC-EVs on lung epithelial cell survival depends 
on the number of EVs administered (Antounians et al., 2019). 
As well as AFSC-EVs, there has also been studies to observe the regenerative potential of 
bone marrow stromal/stem cell derived EVs (BMSC-EVs). Qin et al. demonstrated the in 
vitro osteogenic potential of BMSC-EVs and furthermore, studied their capabilities to 
stimulate bone regeneration in vivo. In this study, the EV-group demonstrated accelerated 
bone regeneration and enhancement in repair. The area density and amount of newly formed 
bones was significantly increased in the EV-group when compared to the control quite clearly 
demonstrating the regenerative capabilities of BMSC-EVs (Qin et al., 2016). 
1.6.5. EVs in drug delivery 
RNA based therapies have proven useful for their specificity and flexibility when it comes to 
targeting the diseased human genome, but common vehicles used for RNA drug delivery are 
usually immunogenic and/or cytotoxic. EVs, on the other hand, have proven to be proficient 
in drug delivery as they are biocompatible with mammalian cells. Due to this, they are 
capable of overcoming cellular and drug delivery barriers such as phagocytosis, 
immunogenicity and cytotoxicity (Usman et al., 2018). 
Usman et al., studied the capabilities of EVs produced by human red blood cells (RBCs) for 
the delivery of therapeutic RNAs. These RBC-EVs were taken up by leukaemia cells and after 
24 h of incubation, a clear uptake of Haemoglobin A was observed which had been absent in 
the untreated cells. Moreover, after a 24 h incubation period, ~99% of these cells were 
positive for fluorescence-labelled EVs demonstrating the capabilities of EVs in RNA drug 
therapies (Usman et al., 2018). 
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1.7. Isolation of EVs 
1.7.1. Differential ultracentrifugation 
Differential centrifugation is the most commonly used method of isolating EVs, particularly 
exosomes, and it is based on several centrifugations, each of which increases in both speed 
and time resulting in smaller particle pellets. These centrifugations are carried out on the 
supernatant of the prior ones while the pellets are discarded with the aim of pelleting the 
exosomes (Cvjetkovic et al., 2014). Floating cells are pelleted first (300 g, 10 ming), then 
ABs (2000 g, 20 min), MVs (16,000 g, 40 min), and then finally the exosomes (100,000 g, 
1h) (Lee et al., 2016). 
This method is low cost, there is a reduced risk of contamination, allows for a large sample 
capacity, and it yields large amounts of EVs. However, it is a time consuming method, 
requires a large starting sample, the exosome preparation may be contaminated with MVs or 
protein aggregates and it is not suitable for use in a hospital setting (Lucchetti et al., 2019). As 
well as this, there can be inconsistencies in isolated materials in different protocols due to 
altered centrifugation duration, relative centrifugal force, temperature and the type of rotor 
used (Cvjetkovic et al., 2014) as a result of which it is hard to obtain a standardised isolation 
method. 
1.7.2. Density gradient centrifugation 
Density gradient centrifugation is a method that separates particles based on their density 
using sucrose or iodixanol (Onódi et al., 2018). This method also allows for the separation of 
subcellular components like mitochondria, peroxisomes, and endosomes. There is also the 
possibility to obtain a pure preparation with no viral contamination when using iodixanol 
preparations, and no additional chemicals have to be used for this method. However, this is a 
complex method of isolation that could lead to the loss of sample or, in the case of sucrose 
density gradient preparation, contamination with viral particles (Konoshenko et al., 2018). 
1.7.3. Size exclusion chromatography 
Size exclusion chromatography (SEC) is based on molecule separation due to size difference. 
A solution containing EVs is run through a column containing sepharose. The sepharose 
beads have pores and any particles larger than 75 nm, such as EVs, cannot enter the beads and 
they elute earlier than the particles that are delayed due to the increased path length. In 
comparison to differential centrifugation and density-gradient ultracentrifugation, protein 
complexes and vesicle aggregation does not occur when using SEC (Böing et al., 2014). 
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1.7.4. EV isolation from SF 
EV isolation from SF has proven to be a challenge due to both the viscosity and composition 
of the fluid (Foers et al., 2018). To decrease the viscosity of SF, it is treated with 
hyaluronidase which has been shown to be a beneficial step in the isolation of CD44+ EVs 
(Boere et al., 2016).  The main method of isolation has been differential ultracentrifugation 
where EVs have been isolated using ultracentrifugation with or without further sucrose 
density gradient purification. These preparations have been shown to include considerable 
levels of non-EV material (Foers et al., 2018). 
Foers et al. used differential ultracentrifugation (DUG) to prepare the EVs and used Western 
blot for analysis and while EV markers were detected, there was also serum albumin, high 
density lipoproteins (ApoA-I marker) and other contaminants that are not associated with 
EVs. When analysed with transmission electron microscopy, amorphous material and areas of 
dense aggregation were observed. Sucrose density gradient ultracentrifugation (SDGUC) was 
also shown to not deplete high density lipoproteins from EV isolations (Foers et al., 2018) 
EVs have also been isolated from SF by SEC. When the achieved fractions were analysed by 
Western blot, fractions 2-4 were shown to include EV markers, serum albumin was eluted in 
fractions 5 and 6, and ApoA-I was present in fractions 4-8. Fibronectin was detected in 
fractions 2-6 and was abundant in fractions 3-5. Negligible levels of serum albumin and 
ApoA-I were detected in fractions 2 and 3 (Foers et al., 2018). 
These results show that SEC is a more efficient method of EV isolation from SF than DUG 
and SDGUC. It was more effective in separating them from serum albumin and high-density 
lipoproteins which remain more abundant when EVs were isolated from SF through 
differential centrifugation and sucrose density gradient ultracentrifugation. 
1.7.5. EV isolation from blood 
EVs are usually isolated from blood plasma instead of blood serum as there is a higher yield 
of EVs and >50% of serum EVs may be platelet derived. The use of an anticoagulant in blood 
samples results in calcium chelations as well as the inhibition of both protease activity and 
platelet activation. Thus, when choosing an anticoagulant, it is important to take into 
consideration further applications. The use of heparin-based anticoagulants is discouraged as 
it is associated with false-negative PCR reads. This is thought to happen because heparin 
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competes with primers and/or enzymes in binding to nucleic acids. As well as this, heparin 
can bind EVs, block EV uptake by cells, and lower the platelet activation threshold. Blood 
treated with ethylenediaminetetraacetic acid (EDTA), dextrose (ACD), or citrate resulted in 
the apparent count of EVs being lowered as calcium chelators promote rapid association of 
EV with platelets (Witwer et al., 2013). It has been shown that platelet EV counts were lower 
in blood samples collected in citrate or EDTA than in those collected in protease inhibitors 
(Szatanek et al., 2015) 
Ultracentrifuge based EV enrichments for plasma have shown high levels of contaminants 
such as high-density lipoproteins and serum albumin  (Foers et al., 2018). Isolation of EVs by 
differential centrifugation has also proven to be ineffective due to the fact that the viscosity of 
the plasma affects the recovery of vesicles (Böing et al., 2014). Thus, combining different 
methods of isolation and purification is best when isolating EVs from blood. 
SEC has proven to be efficient in EV purification from complex biological fluids such as 
blood and blood plasma. It avoids high centrifugal force which usually leads to vesicle rupture 
and aggregation and it is also capable of separating EVs from serum albumin (Foers et al., 
2018). Despite this, Karimi et al. showed that SEC alone is not effective in removing 
lipoproteins and plasma proteins from fractions that also contained EVs and EV markers. SEC 
removes lipoprotein particles that have a similar density to EVs but are different sizes. The 
solution to this was combining density gradient centrifugation with SEC as density gradient is 
capable of separating EVs from lipoproteins of similar size but have different densities. This 
resulted in Karimi et al. obtaining a purer sample as the lipoprotein particles and plasma 
particles were removed. To further increase the yield of EVs, the plasma was ultracentrifuged 
and the pellets were dissolved in PBS. This has the added benefit of being able to start with 
any volume of plasma. Then this mixture was purified using density gradient, and SEC. As a 
result, more vesicles were present in certain fractions when compared to fractions where 
ultracentrifugation were not used (Karimi et al., 2018). 
Onódi et al. isolated EVs from blood plasma by iodixanol density gradient ultracentrifugation 
(DGUC) followed by bind-elute SEC. The use of DGUC decreased the lipoprotein 
contamination while also keeping the high separation efficiency. Further purification through 
bind-elute SEC resulted in a decreased yield but lipoproteins and albumin were removed 
while certain blood components were not (Onódi et al., 2018). 
Serum is a rich source of EVs but separating EVs from serum proteins and non-EV lipid 
particles has proved to be a challenge. Exoquick plus (polymer-based precipitation; System 
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Biosciences) and SEC fraction 7 and 8 yielded the largest number of particles isolated but 
lipoprotein markers such as APOB and APOE were most abundant using these methods. 
However, if SEC fractions were purified using iodixanol density gradient centrifugation 
followed by ultracentrifugation, a lower particle to protein ratio was observed (Brennan et al., 
2020). 
In conclusion, there seems to be no one certain method that can be used to isolate EVs from 
blood. Each method seems to have their own downfalls which can be compensated for by 
combining them with other isolation and purification methods.  
1.8. Analysis of EVs 
1.8.1. Nanoparticle tracking analysis 
Nanoparticle tracking analysis (NTA) is based on the “characteristic movement of  
(nano)particles in solution according to the Brownian motion“ (Bachurski et al., 2019). 
Brownian motion is used to describe the uncontrolled movement of particles in a liquid as 
they collide with other particles (Floyd et al., 2017). The movement of these particles is 
recorded by a camera when light is scattered by a laser illuminating particles during which the 
smaller particles move faster than the bigger ones. Through the use of NTA, it is possible to 
determine both the size and concentration of samples (Bachurski et al., 2019). 
The NTA devices used are NanoSight NS300 (Malvern, UK) and ZetaView (Particle Metrix, 
Germany). Both devices allow for the determination of size and concentration of samples but 
differ in their composition of hardware and software (Bachurski et al., 2019). 
Both devices fail to detect EVs smaller than 50 nm. ZetaView is more accurate in measuring 
concentration while NS300 is more accurate in measuring size. ZetaView is also more 
capable of accurately measuring sequentially diluted EV samples and has also been proven to 
be more sensitive to the changes in concentration of an EV sample after multiple freeze-thaws 
which results in EV degradation. NanoSight NS300, on the other hand, does not detect these 
differences (Bachurski et al., 2019). 
1.8.2. Other methods of analysis 
Other methods used in the analysis of EVs are western blot and transmission electron 
microscopy (TEM). Tetraspanins CD9, CD63 and CD81 are general EV markers (Campos-
Silva et al., 2019) used in these methods to ascertain the presence of these vesicles. Western 
blotting also allows to attain the purity of the sample (Mahmood and Yang, 2012). 
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TEM can be used to determine the quality and purity of EVs (Rikkert et al., 2019) but it can 
also be used to attain information on the biochemical properties of EV surface proteins with 
the aid of immunogold labelling. EVs have to be fixed and dehydrated when using TEM 
(Cizmar and Yuana, 2017) and the method itself is both time consuming and technically 
challenging (Bachurski et al., 2019). However, it is possible to analyse frozen samples 
through the use of cryo-TEM without having to fixate/dehydrate the EVs and it is possible to 
detect EV surface proteins using immunogold labelling but this method can also be 
technically demanding (Cizmar and Yuana, 2017). 
1.9. Osteoarthritis 
Osteoarthritis is the most common form of arthritis and it affects the tissues of the joint such 
as the cartilage, bone, and capsule, but also ligaments, and muscles. Typically, this disease 
affects the hips, hands, and knees but it can also develop in other joints. It is considered a 
chronic disease and has no preventable cure. However, there are treatments that can reduce 
pain, improve function, and delay the progression of the disease (OARSI, 2016). OA can be 
defined in three ways: clinically, radiologically, or symptomatically. Clinical OA is diagnosed 
based on symptoms and a physical examination, radiological OA is diagnosed based on the 
presence of osteophytes, and symptomatic OA is diagnosed based on a patient experiencing 
frequent pain and radiographic evidence (Lawrence et al., 2008). 
The prevalence of OA has been increasing throughout the years. It has been estimated that 27 
million US adults (Lawrence et al., 2008) and >40 million Europeans have OA (Kingsbury et 
al., 2014). In the UK, approximately 8.5 million have clinical OA. The prevalence of which 
increases with age; 13.9% of people aged 25 and over had OA of at least one joint, while 
33.6% of people aged 65 and over had OA (Neogi, 2013). In Estonia in 2016, it was estimated 
that there were 33,018 men and women of all ages with OA, the prevalence of which 
increased significantly after the age of 35. After the age of 45, the number of women with OA 
doubled relative to men (Tervise Arengu Instituut, 2016).  
A characteristic of OA is unpredictable, intermittent pain which has been shown to have a 
bigger impact on the quality of life than constant pain in OA patients. The pain negatively 
impacts an individual’s mood, participation in social and recreational activities, and sleep 
(Neogi, 2013). It also impacts an individual’s capability to do everyday activities which, as a 
result, affect the quality of life. Many with OA avoid exercise/sport, gardening, and climbing 
stairs while also requiring assistance with cleaning and dressing (D. J. Hunter and Riordan, 
2014). 
26 
 
1.9.1. OA pathogenesis 
OA has many risk factors including obesity, sex, race and ethnicity, genetics, nutrition, 
smoking, and injuries/trauma to the joint. In the case of genetic predisposition, there is a 
possibility that it will not develop unless if there has been joint trauma or if they express one 
or more of the other risk factors (Kapoor, 2015). OA pathogenesis is characterised by the 
degradation of the articular cartilage, remodelling of the subchondral bone, formation of 
osteophytes, synovitis, degeneration of menisci, and hypertrophy of the joint capsule 
(Robinson et al., 2016). Figure 5 describes characteristic differences between a normal and 
OA joint. 
 
 
 
Figure 5. A comparison between a healthy and OA joint. The changes that occur in the 
progression of the disease are highlighted (Robinson et al., 2016). 
The articular cartilage is composed of the extracellular matrix (ECM) and chondrocytes (Fox 
et al., 2009) and contains no blood vessels, nerves, or lymphatic vessels (Blalock et al., 2015). 
The ECM itself is made up of water, type II collagen fibres, and proteoglycans, and to a lesser 
extent, glycoproteins and non-collagen proteins. All of these components facilitate water 
retention within the ECM, which is important for maintaining the mechanical properties of the 
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articular cartilage, like its elasticity and tensile strength (Fox et al., 2009;Heijink et al., 2012). 
Proteoglycans have a rapid turnover rate while collagen does not. The turnover of 
proteoglycans and collagens is mediated by chondrocytes, which synthesize these along with 
the proteolytic enzymes needed for their breakdown. Chondrocytes themselves are influenced 
by both growth factors and cytokines (Man and Mologhianu, 2014). Osteoarthritis occurs 
when the chondrocytes are incapable of maintaining the homeostasis between the synthesis 
and degradation of the ECM components. When this homeostasis is disrupted, the water 
content in the ECM increase while the proteoglycan content decreases which weakens the 
collagen network as there is a decrease in the synthesis of type II collagen and an increase in 
the breakdown of existing collagen. As well as this, apoptosis of chondrocytes increases due 
to compensatory mechanisms. At first, the increased synthesis of matrix molecules and 
proliferation of chondrocytes is capable of maintaining the integrity of the cartilage, but 
eventually the loss of chondrocytes and changes in the ECM cause the development of 
osteoarthritis (Heijink et al., 2012). 
The subchondral bone is separated from the articular cartilage by a zone of calcified cartilage 
and it consists of the subchondral bone plate, trabecular bone and bone marrow space. The 
properties of the subchondral bone are modified through remodelling and modelling. 
Remodelling is a result of bone resorption and new bone formation of a resorbed surface. 
Modelling, on the other hand, causes changes in the architecture and volume of the bone. As a 
result of osteoarthritis, these mechanisms can be altered causing structural changes in the 
subchondral bone. These changes result in an increased thickness of the subchondral bone 
plate, modifications in the architecture of subchondral trabecular bones and the formation of 
osteophytes which is the formation of new bone at the joint margins (Man and Mologhianu, 
2014). 
The joint capsule is very important in joint functionality as it seals the SF within the joint, 
limits joint movement resulting in passive stability and provides active stability as well. 
Collagen fibres within the bone adhere to bone using fibrocartilaginous attachment. Blood 
vessels and nerves pass through the capsule to supply it and the synovium (Blalock et al., 
2015).  
The synovial membrane consists of metabolically active cells named synoviocytes, which are 
important as they nourish chondrocytes and remove metabolites and products of matrix 
degradation. Synovitis occurs due to the inflammation of the synovium and it is responsible 
for many clinical symptoms (Sellam and Berenbaum, 2010). Synovitis is thought to be caused 
by cartilage matrix proteolytic degradation products and other factors such as microcrystals 
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and abnormal mechanical stress. These components are released into the SF and go through 
phagocytosis because of the macrophages in the synovial lining, which results in the synthesis 
of mediators that lead to the inflammation of the synovium. These mediators diffuse into the 
cartilage through the SF and this continues in a vicious circle which results in increased 
cartilage degradation and an increase in inflammation. Synoviocytes are also capable of 
producing proinflammatory cytokines such as IL-1β, IL-6 and TNFα which are thought to 
mediate the progression and pain related to this disease (Man and Mologhianu, 2014). 
Another feature of OA are meniscal tears. Menisci are fibrocartilaginous, wedge-shaped 
structures that take part in joint stability, load distribution, shock absorption, and lubrication 
(Blalock et al., 2015). Degraded menisci appear torn, fissured, fragmented, macerated or 
completely destroyed and this process begins within the substance of the tissue (Man and 
Mologhianu, 2014). Loss of a substantial amount of meniscal tissue permanently changes the 
biochemical and biological environment of the knee joint (Heijink et al., 2012). Tissue 
disruption occurs at the inner rim and spreads to the articular surfaces of the meniscus. This 
leads to a loss of meniscus tissue in the avascular zone. Type I and type II collagen content 
decreases from the surface, middle and deep zone while the proteoglycan content increases in 
the menisci. All of this contributes to meniscal degeneration and reduced tensile strength. The 
ability of the meniscus to withstand loading and force transmission results in degenerative 
tears (Man and Mologhianu, 2014). 
1.9.2. Current management strategies 
Clinical end stage treatment of OA is artificial joint replacement but treating early stage OA 
through non-surgical techniques is preferable for patients (T. Sun et al., 2018). A novel 
strategy for OA treatment is synergistic therapy (Ji and Zhang, 2019). However, in general, 
OA is treated with the help of medications, nondrug therapies or a combination of both 
(Arthritis Foundation, n.d.). 
Synergistic therapy combines enhanced joint lubrication and drug delivery in OA treatment 
(Ji and Zhang, 2019). For instance, nanoparticles were used for both joint lubrication and as 
nanocarriers for aspirin. The results showed that 67% of aspirin was released in 24 hrs, 74.5% 
in 72 hrs while without a carrier, 100% was released in 5 hrs (G. Liu et al., 2014).  
Numerous different pain and anti-inflammatory medicines exist for OA. Firstly, there are 
analgesics which are pain relievers that include acetaminophen and opioids. Secondly, there 
are nonsteroidal anti-inflammatory drugs (NSAIDs). These are used to ease inflammation and 
they include aspirin, ibuprofen, naproxen and celecoxib. Counterirritants are used to irritate 
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nerve endings causing the painful area to feel cold, warm or itchy which takes focus away 
from the actual pain. Corticosteroids are anti-inflammatory medicines that work similarly to 
the cortisol hormone. Hyaluronic acid injections are also used in OA treatment. This helps to 
reduce or relieve inflammation as the gel aids in restoring lubrication and inducing the growth 
of new cartilage and bone tissue. Also, platelet-rich plasma (PRP) is used in treatment as it 
contains proteins that help to ease pain and inflammation. Lastly, other drugs such as the anti-
depressant duloxetine and the anti-seizure drug pregabalin are used to treat OA pain too 
(Arthritis Foundation, n.d.).  
Non-drug therapies include exercise, weight loss and surgery. Exercise is important as 
movement is essential in OA treatment. Strengthening exercises help to build muscle around 
the painful joints and ease the stress. Range-of-motion exercise or stretching help to reduce 
stiffness. Aerobic and cardio help improve stamina and energy levels and reduce stress. 
Lastly, balance exercises help strengthen small muscles around knees and ankles and help 
prevent falling which would only exacerbate the injury. Losing weight helps reduce pain as 
well as stop or slow down joint damage. For every pound lost, four pounds of pressure is 
removed on lower-body joints. Finally, as mentioned before, surgery is a form of treatment, 
but it is a last resort in late-stage OA when no other treatment options will aid in OA 
management (Arthritis Foundation, n.d.). 
2. RESEARCH OVERVIEW 
2.1.  Aims of the study 
The general aim of this study was to study to the transcriptomic profile of EVs in SF and 
blood of OA patients in order to define potential biomarkers for early OA diagnosis. The 
specific objectives of my research were: 
 To give an overview of the current knowledge about OA transcriptomic profile. 
 To give an overview of the OA studies regarding EVs derived from tissues, more 
specifically SF and blood derived EVs of OA patients. 
 To further analyse the role of miR-146a and miR-26b in OA. 
 To evaluate the potential of using EVs as biomarkers for OA diagnosis. 
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2.2. Materials and methods 
PubMed (PubMed) was the main database used for research on this topic. All used articles 
were written in English. Key words used to find articles were “extracellular vesicles” and 
“osteoarthritis”. These key words were used both separately or combined with “blood”, 
“serum”, “plasma”, “synovial fluid”, “joint fluid” “transcriptome”, “exosome”, 
“microvesicle”, “apoptotic bodies”, “extracellular RNA”, “RNA”, “miRNA”, “miR-146a”, 
“miR-26b”. 
Some miRNA target genes were found in articles while other target genes and their respective 
target scores were found through the use of MicroRNA Target Prediction Database (MiRDB - 
MicroRNA Target Prediction Database). According to MiRDB, a predicted target with a 
prediction score of 80 or higher is most likely to be real. If the score is below 60, then there is 
a need for caution, and it is recommended to have supported evidence. As well as using 
MiRDB to find target genes, TargetScan Database (TargetScanHuman 7.2) was used to 
confirm the miRNA targets. 
2.3. Results and discussion 
2.3.1. General OA transcriptome profile 
At least one publication was found for each tissue listed in Table 2 (p.31) that carried out an 
in-depth analysis of the OA transcriptomic profile. However, if more than one publication was 
found regarding the same tissue, the most recent article was used. 
Dysregulation in the transcriptome leads to the differential expression of genes which 
contributes to the pathogenesis of OA. These differentially expressed genes (DEGs) have 
been found in various OA tissues such as the cartilage, chondrocytes, subchondral bone, 
meniscus and synovial tissue which is shown in Table 2 (p.31). The most notable 
dysregulation of RNAs occurs in chondrocytes and this dysregulation can lead to chondrocyte 
apoptosis. Chondrocyte apoptosis is one of the key features of cartilage degradation, which in 
turn is a key characteristic of OA. There has been shown to be a significant positive 
correlation between the severity of OA and the number of apoptotic chondrocytes in OA 
cartilage (p = 0.016) (Zhong et al., 2016). Therefore, it is possible to conclude that the tissues 
with higher amounts of DEGs are more affected by the disease.  
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Table 2. The dysregulation of RNA species in various OA tissues. up – up-regulated RNAs; 
down – down-regulated RNAs; PBMC – peripheral blood mononuclear cells; dmg – damaged 
regions; undmg – undamaged regions. 
Tissue Method of 
Analysis 
Sample size RNA  
species 
Dysregulation Ref 
 
Cartilage RNA-seq, 
qPCR 
9 (all OA; 
dmg vs. 
undmg) 
mRNA 401 up 
338 down 
(H. Li et 
al., 2019) 
Meniscus Microarray, 
qPCR 
24 (12 OA, 
12 non-OA) 
mRNA 75 up 
93 down 
(Brophy 
et al., 
2018) 
Synovial 
tissue 
qPCR 50 (22 OA, 
28 non-OA) 
mRNA 145 up 
84 down 
(Z. Li et 
al., 2019) 
Subchondral 
bone 
Microarray, 
qPCR 
25 (20 OA, 
5 non-OA) 
Total 
RNA 
420 up 
552 down 
(Chou et 
al., 2013) 
Articular 
chondrocytes 
Microarray 20 (12 OA, 
8 non-OA) 
Total 
RNA 
888 up 
732 down 
(Aki et 
al., 2018) 
PBMC Microarray 41 (19 OA, 
22 non-OA) 
mRNA 791 up 
440 down 
(Shi et al., 
2019) 
Serum qPCR 24 (12 OA, 
12 non-OA) 
miRNA 205 up 
74 down 
(Ntoumou 
et al., 
2017) 
 
To further understand the effect that the dysregulation of RNA molecules has on OA 
pathogenesis, DEGs with the highest significance according to the publications listed in Table 
2 were studied.  
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Table 3. The top five DEGs found in OA tissues and the affected pathways, which were 
chosen based on either their p-value or what the authors of the article emphasised. The 
number of DEGs can be seen in Table 2. GO – gene ontology. RA – rheumatoid arthritis. 
PPAR – peroxisome proliferator-activated receptors. AMPK – AMP-activated protein kinase. 
MAPK – mitogen-activated protein kinase. 
Tissue  Top DEGs Pathways Ref 
Cartilage  WISP2, ATF3, 
CHI3L1, ADAM12, 
COL3A1 
ECM-receptor interaction, TGF-β 
signalling, osteoclast differentiation, 
insulin signalling 
(H. Li et 
al., 2019) 
Meniscus CSN1S1, 
COL10A1, WIF1, 
SPARCL1, VEGFA 
Response to external stimuli, 
regulation of inflammatory response, 
immune system, response to wounding 
(Brophy et 
al., 2018) 
Synovial tissue ADIPOQ, IL6, 
CXCR1, IL8, 
CXCL1 
Cytokine-cytokine receptor 
interaction, chemokine signalling 
pathway, RA, TNF signalling 
pathway, PPAR signalling pathway, 
AMPK signalling pathway 
(Z. Li et 
al., 2019) 
Subchondral 
bone 
COL3A1, TUBB3, 
PPEF1, DIO2, 
TNSFS11 
Lipid and mineral metabolism, 
connective tissue disorders, cellular 
growth and proliferation 
(Chou et 
al., 2013) 
Articular 
chondrocytes 
COL2A1, ASPN, 
IGFBP7, FOXO1, 
COL3A1 
ECM-receptor interaction, focal 
adhesion, protein digestion and 
absorption pathways 
(Aki et al., 
2018) 
PBMC RPL38, P1K3CD, 
MAPK14, IL1A, 
JUND 
Osteoclast differentiation pathway, 
MAPK signalling pathway 
(Shi et al., 
2019) 
Serum INSR, IGF1R, 
CREB5, NFκB, 
TNFα 
ECM-receptor interaction, TGF-β 
signalling pathways, Wnt, FoxO, 
mTOR, pI1K/akt, MAPK 
(Ntoumou 
et al., 
2017) 
 
It has been demonstrated that in OA pathogenesis the expression of genes that participate in 
certain pathways has been altered and this affects the functionality of the pathway. One of the 
affected pathways is the ECM-receptor interaction pathway and this has been demonstrated in 
the cartilage, articular chondrocytes and serum (Table 3). Structural matrix macromolecules in 
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the ECM and growth factors regulate chondrocyte functions through specific membrane 
receptors. DEGs such as collagen type II alpha 1 chain (COL2A1) (chondrocytes, Table 3) 
and COL3A1 (chondrocytes and cartilage, Table 3) are involved in the ECM-receptor 
interaction pathway. COL2A1 takes part in the metabolic activation of OA (J. Sun et al., 
2015) while COL3A1 is important in cartilage function (He et al., 2016) and has been shown 
to correlate with radiographic severity of canine elbow OA (Clements et al., 2009). Therefore, 
based on these findings it is clear to see that that the ECM-receptor interaction is important in 
chondrocyte functionality and any alterations in this pathway can contribute to the 
pathogenesis of OA. 
Another pathway affected by the dysregulation is TGF-β signalling as well as the osteoclast 
differentiation pathway. TGF-β signalling has been shown to occur in the serum as well as the 
chondrocytes in cartilage (Table 3, p.32). ASPN in chondrocytes codes for a protein named 
asporin which is a component in the ECM. Asporin binds to collagen fibres to induce 
mineralization and it also inhibits TGF-β induced cell type differentiation (Aki et al., 2018). 
TGF-β plays a role in the development and homeostasis of tissues by regulating proliferation, 
differentiation, apoptosis and migration, as well as controlling ECM synthesis and 
degradation (Blaney Davidson et al., 2007). Furthermore, osteoclast differentiation was 
observed in the cartilage and PBMCs (monocytes differentiate into osteoclasts). Osteoclasts 
are cells that degrade bone during bone remodelling in both normal and pathologic states 
(Boyce et al., 2009). The differentiation, activity and survival of osteoclasts is highly 
regulated in non-OA individuals but in OA patients, osteoclastogenesis is increased, 
resorption is elevated, and apoptosis of osteoclasts is reduced (Löfvall et al., 2018). 
Therefore, it is evident that osteoclast differentiation and TGF-β signalling also play an 
important role in OA pathogenesis. From this it is possible to conclude that the altered 
expression of certain genes affects the functionality of pathways which, in turn, contributes to 
OA progression.  
It is evident that these previously discussed changes in gene expression have contributed to 
the pathogenesis of OA. Despite this, there is no correlation between the SF and plasma 
miRNA profile (Murata et al., 2010). Therefore, it is not possible to compare the 
transcriptomic profile of the two for OA diagnostic purposes. However, since EVs are capable 
of transporting and protecting their RNA cargo, the transcriptomic profile of EVs from OA 
tissue could possibly be used in OA diagnostics. We hypothesized, that the EVs could be 
migrating from the SF into the peripheral blood and through comparing miRNAs in both the 
blood and SF, it could be possible to determine a set of miRNAs that could act as a specific 
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OA biomarkers. This would prove to be a much more effective way of diagnosing OA taking 
a blood sample is much easier and less invasive compared to collecting SF. 
2.3.2.  EVs derived from OA tissues  
The amount of publications to be found on the OA-EV transcriptomic profile is very small 
and only one article was found that provided an in-depth analysis of the SF-EV profile. 
Furthermore, two other articles were found, one regarding the exRNA profile in SF and 
another regarding EVs in plasma. The EV transcriptomic profile is important as we think it 
might be possible to compare SF and blood EV-miRNA profile for OA diagnostics. It has 
already been shown that the expression patterns of exosomal miRNA can differ from 
intracellular miRNA. These miRNAs were isolated from MC/9 cells, human mast cells and 
bone marrow mast cells. They found that some of the miRNAs were expressed at higher 
levels in exosomes than in cells (Valadi et al., 2007). This combined with the fact that EV-
miRNA content varies between OA and non-OA patients (Esa et al., 2019; Kolhe et al., 
2017), there is a possibility that EV-miRNAs can be used as OA diagnostic tools.  
Table 4 (p.35) shows the dysregulation of different exosome derived or extracellular RNAs 
(exRNA) in SF and plasma. When comparing Table 4 (p.35) and Table 2 (p.31), it is clear to 
see that in the case of OA the number of RNAs dysregulated in solid tissues is much higher 
than the RNAs dysregulated in EVs from SF and plasma. If a miRNA subtype can be found to 
be similarly regulated in both solid tissues and SF and plasma, it could prove to be a possible 
biomarker for OA. For this reason, it is important to find specific RNA molecules that are 
similarly regulated in both OA tissue and in EVs derived from OA tissue. However, if the 
content of EVs derived from OA tissue and non-OA tissue varies, then it does not matter if 
the content matches the RNA profile inside the cells. The difference in the EV-RNA profile 
can be used as biomarkers. Therefore, first the content of EVs dervied from OA and non-OA 
tissue should be analysed first and then decided if a comparison to the RNA profile of cells is 
needed. 
It is also worth noting that the study done by Aae et al. (Table 4, p.35) evaluated plasma EV-
miRNAs as possible biomarkers for OA but the levels of plasma EV-miRNAs were similar 
for all participants, OA and non-OA alike. However, this study focused on the general EV-
miRNA profile rather than on specific miRNA subtypes that could be potential biomarkers for 
the disease. As well as this, they focused on EVs in general which means that this study 
evaluated the exosome, MV and AB miRNA content rather than just focusing on the 
exosomal miRNA content as most studies do. Also, the miRNA cargo within exosomes seems 
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to be gender specific (Kolhe et al., 2017) and this was not a factor considered in the study 
done by Aae et al. Therefore, it could still be possible to find biomarkers for OA in plasma.  
Table 4. The dysregulation of RNA populations in EVs and their method of analysis. up – up-
regulated; down – down-regulated; m – male; f – female; NGS – next generation sequencing. 
Tissue Method of 
Analysis 
Sample 
size 
Origin of 
RNA 
RNA 
species 
Dysregulation Ref 
SF Microarray, 
qPCR 
51 (33 
OA, 18 
non-OA) 
Exosomes miRNA 45 up,  
68 down (m) 
53 up,  
91 down (f) 
(Kolhe et 
al., 2017) 
SF Total RNA-
seq 
19 (14 
knee 
trauma, 5 
healthy) 
Extracellular miRNA 
mRNA 
3 up, 5 down 
44 up, 25 
down 
(Griswold 
et al., 
2018) 
Plasma NGS 46 (23 
OA, 23 
non-OA) 
EVs miRNA - (Aae et 
al., 2020) 
 
Murata et al. have already discovered that the expression patterns of extracellular miRNAs in 
OA-SF were similar to miRNAs secreted by synovial tissues (Murata et al., 2010). Based on 
Table 4 it is possible to see that the number of differently expressed miRNAs in exosomes is 
much higher than that of extracellular RNA (exRNA) in the SF. The lower number of exRNA 
populations could be explained by RNA degradation in the SF while exosomal miRNAs were 
protected from it. This shows that investigating exosomal miRNA is much better for the 
purpose of our study as the likelihood of obtaining intact RNAs is higher. Furthermore, it 
could be possible to compare the whole miRNA content with EV-miRNA content. Murata et 
al. believed that plasma miRNAs are generated by various tissues (Murata et al., 2010) which 
could include synovial tissue. Therefore, based on previous research done on the topic, we can 
hypothesize that some of the SF-EVs derived from cartilage will potentially be transported 
into the peripheral blood. However, how slow or fast this migration could occur is unknown. 
As I mentioned before, one of the possible reasons why Aae et al. did not detect any 
differences in the plasma EV-miRNA content for early-stage OA and non-OA patients is 
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because not enough miRNAs had migrated yet. Nevertheless, this does not mean that it is not 
possible to find differences in expression at later stages of the disease. 
Table 5. The presence of specific miRNAs in SF-EVs, and the possible origin of SF-EVs in 
OA patients. This table was composed by comparing a list of miRNAs believed to partake in 
OA pathogenesis (Panagopoulos and Lambrou, 2018) with a list of gender specific miRNAs 
found to be significantly dysregulated in SF-EVs (Kolhe et al., 2017). Only miRNA 
molecules present in both studies were included. m – male; f – female; down – down-
regulated; up – up-regulated. 
miRNA Tissue Origin EVs Ref 
miR-23a-
3p 
Cartilage 
SF 
Chondrocytes 
Cells in SF 
SF-EVs (f, 
down) 
Kang et al., 2016  
Y.-H. Li et al., 2016 
miR-24 Cartilage 
SF 
Chondrocytes 
Cells in SF 
SF-EVs (f, 
down) 
Philipot et al., 2014 
Y.-H. Li et al., 2016 
miR-26a Cartilage Chondrocytes SF-EVs (f, 
down) 
Rasheed et al., 2016 
miR-26b Cartilage 
 
Chondrocytes 
 
SF-EVs 
(m, up) 
Hu et al., 2018; Xuefeng 
Yin et al., 2017 
miR-146a Cartilage 
Cartilage 
Chondrocytes 
Chondrocytes 
SF-EVs (f, 
down) 
Yamasaki et al., 2009 
J. Li et al., 2012 
 
However, the purpose of this study is to give an overview into the current knowledge on the 
transcriptomic profile of EVs found in SF and blood in the case of OA. As the blood profile 
of EV-miRNAs in OA is not yet well studied, more emphasis will be placed on SF EV-
miRNAs and their potential in OA diagnosis. This will be done through determining if the 
chosen miRNA molecule has been analysed in the blood and if its expression can be related 
back to its expression in OA tissue and SF-EVs. If this comparison is successful, then it might 
also be possible that the expression of the blood EV-miRNAs will be similar due to migration 
from the SF into the peripheral blood. This migration is made possible by the phospholipid 
bilayer that surrounds EVs and protects their cargo. From Table 5, it is clear to see that 
miRNAs found in chondrocytes have also been found in SF-EVs and exRNAs have been 
found in the SF. Therefore, it is highly likely that some of the miRNAs found in SF-EVs 
could originate from chondrocytes.  
37 
 
Several miRNAs have been found to play a role in OA pathogenesis and Table 5 reflects a 
small portion of them. This table was narrowed down to the miRNAs that were also found to 
be expressed in SF-EVs. miR-23a-3p is thought to contribute to OA progression by targeting 
SMAD3 and thus, affecting the levels of type II collagen and aggrecan (Kang et al., 2016). 
miR-24 has been shown to be a negative regulator of a senescence marker p16INK4a. 
Overexpression of INK4a in chondrocytes induced the production of MMP1 and MMP13 
which lead to senescence being linked with OA pathogenesis (Philipot et al., 2014). Lastly, 
miR-26a has been shown to be a direct regulator of inducible nitric oxide synthase (iNOS) 
expression which has been associated with the pathogenesis of OA (Rasheed et al., 2016). 
The rest of this study will focus on analysing the possibility of miR-146a and miR-26b being 
used as biomarkers for diagnosing OA. 
2.3.3. miR-146a and miR-26b in OA 
No miRNAs were found to be dysregulated in both male and female OA patients SF-EVs that 
have also been studied in OA pathogenesis so instead, focus will be turned to one miRNA 
found to be dysregulated in female OA patients SF-EVs and one miRNA dysregulated in male 
OA patients SF-EVs. For this reason, miR-146a and miR-26b were chosen. miR-146a was 
found to be significantly (p = 0.00065) dysregulated in only female patients’ SF-EVs while 
miR-26b was found to be significantly (p = 7.02E-05) upregulated in male SF-EVs.  
A table was composed to help evaluate the possibility of using miR-146a and miR-26b as 
biomarkers through showing their predicted targets that have a known role in OA 
pathogenesis (Table 6). Through this, the possible role of these two miRNAs in OA 
pathogenesis will be demonstrated. Furthermore, based on this information we can give a 
preliminary evaluation if miR-146a and miR-26b are viable biomarkers for early OA 
diagnostics.  
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Table 6. miR-146a and miR-26b and their predicated targets. Some target genes were 
identified through articles (which are referenced) while others were identified through the use 
of MiRDB (MiRDB - MicroRNA Target Prediction Database, n.d.) and TargetScan 
(TargetScanHuman 7.2, n.d.) databases. I chose these targets as I could find publications that 
linked these target genes to OA. 
miRNA Target genes Target score Ref 
miR-146a MMP13 
SMAD4 
MMP16 
- 
- 
89 
Yamasaki et al., 2009 
J. Li et al., 2012; TargetScan 
X. Li et al., 2011; MiRDB 
miR-26b KPNA3 
KPNA2 
COL10A1 
PTGS2 
- 
95 
97 
96 
Xuefeng Yin et al., 2017 
MiRDB 
MiRDB 
MiRDB 
 
2.3.3.1. miR-146a 
miR-146a expression can be induced by toll-like receptor (TLR) agonists, TNF-α or IL-1β 
(Song et al., 2017) and it has been associated with numerous pathologies. It has been shown 
to affect cancer, inflammation and the innate immune response. Overexpression of miR-146a 
causes inhibition of NF-κB signalling, FOXP3-induced cellular apoptosis and PDGF-
stimulated tumour growth while downregulation has been shown to contribute to 5q- 
syndrome (bone marrow disorder that results in too many immature blood cells and too few 
normal mature blood cells). It has also been implicated in cardiovascular diseases. 
Upregulation of miR-146a has been shown to contribute to coronary artery disease, 
atherosclerotic plaque formation, and attenuation of proinflammatory stress in 
hyperlipidaemia (Paterson and Kriegel, 2017). However, miR-146a has also been shown to 
have therapeutic potential as exosomal miR-146a has been shown to contribute to the 
increased therapeutic effects of IL-1β-pre-treated MSCs on cecal ligation and puncture-
induced sepsis (Song et al., 2017). miR-146a seems to be a multifaceted RNA molecule but 
most studies have focused on its inflammatory effect and not much attention has been paid to 
the possible therapeutic potential of exosomal miR-146a. 
In OA, the dysregulation of miR-146a seems to depend on the stage of the disease. Most 
studies have focused on the upregulation of miR-146a which seems to occur in early OA 
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while down-regulation seems to occur in late-stage OA. In OA patients’ cartilage, miR-146a 
was upregulated in grade I OA (grade I = mild OA scored 0-5 according to a modified 
Mankin score) (Yamasaki et al., 2009) while it was seen to be downregulated in grades II and 
III (grade II = moderate OA scored 6-10, grade III = severe OA scored 11-14). While the 
expression of miR-146a decreased in grade II, the expression of matrix metalloproteinase 13 
(MMP13) increased. Some believed miR-146a to be a negative feedback regulator of MMP13 
and while miR-146a expression seems to decrease in accordance with the levels of MMP13 
expression, this is speculation and has not been proven (Yamasaki et al., 2009). However, 
MMP13 has been shown to be expressed in OA cartilage and it has the highest activity in the 
degradation of cartilage-specific type II collagen (N.-G. Li et al., 2011). As well as MMP13, 
MMP16 is another predicted target of miR-146a. Upregulation of miR-146a suppresses 
MMP16 which is an important activator of MMP2 (X. Li et al., 2011). As miR-146a is down-
regulated in stages II and III which means MMP16 is not suppressed anymore and therefore, 
its target MMP2 is active which consequently also affects the pain experienced during OA. 
This demonstrates that miR-146a might play a role in OA cartilage pathogenesis and OA 
pain-related pathophysiology.  
miR-146a is also predicted to target Smad4 in chondrocytes from tibial plateaus and femoral 
condyles. Smad4 plays an important role in chondrocyte differentiation by inhibiting 
hypertrophy and cell apoptosis. Smad4 is required for the normal organization of the cartilage 
growth plate (J. Zhang et al., 2005) and it’s absence is characterized by reduced chondrocyte 
proliferation, increased hypertrophic differentiation, and apoptosis (J. Li et al., 2012). 
Overexpression of miR-146a inhibited Smad4 protein levels while downregulation of miR-
146a results in the upregulation of Smad4. Evidently, upregulation of miR-146a plays a role 
in OA pathogenesis. 
The presence of miR-146a has also been proven in both serum and plasma samples. A study 
compared cartilage and serum samples from OA patients to samples from patients with 
femoral neck fractures with no radiological symptoms or hip joint pain. It was found that 
miR-146a was significantly overexpressed in OA patients’ cartilage and serum with a positive 
correlation between the levels in both (Skrzypa et al., 2019). miR-146a was also found to be 
overexpressed in the plasma of early-stage OA patients (Cuadra et al., 2014) while the 
concentration of miR-146a in SF was lower than in plasma. In another study where plasma 
and SF samples from late-stage OA patients were compared it was found that miR-146a levels 
were significantly higher in rheumatoid arthritis SF than in OA-SF (Murata et al., 2010). 
However, Guan et al. demonstrated that miR-146a is downregulated in late-stage OA patients 
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cartilage (Guan et al., 2018) which is supported by another study (Yamasaki et al., 2009). 
This shows that the expression patterns of miR-146a depends on the stage of the disease and 
that it is highly likely that this expression pattern is mirrored in the blood. 
As mentioned before, miR-146a was found to be significantly down-regulated in female OA 
patients SF-EVs (Kolhe et al., 2017). In this study the OA-SF samples were received from 
knee joints of patients undergoing total knee arthroplasty procedures. A specific OA stage 
(early or late) was not given but total knee arthroplasty is a clinical end stage treatment of OA 
therefore it is possible to conclude that these samples came from patients with late-stage OA. 
As these donors potentially had late-stage OA, it is very likely that miR-146a in SF-EVs are 
similarly dysregulated as the miR-146a found in OA blood and tissue samples. Therefore, it is 
likely that miR-146a is up-regulated in early-stage OA SF-EVs and down-regulated in late-
stage OA SF-EVs. 
Overall, miR-146a seems to be upregulated in early stage OA but down regulated in late 
stage. The upregulation in the early stages might be a compensating mechanism to avoid the 
degradation of cartilage. Thus, it is inhibiting MMPs to avoid degradation, but on the other 
hand it affects Smad4, which causes a malfunction in cartilage formation.  It is evident that 
miR-146a could play an important role in OA pathogenesis and could also prove to be a 
possible biomarker for the disease, especially early-stage OA as it is upregulated then. As 
well as this, it has been detected in synovial tissue, plasma, serum, and SF-EVs. Plasma 
miRNAs originate from various tissues and EVs can transport intact RNA molecules due to 
their phospholipid bilayer. Therefore, it is possible that some of the EVs from the joint tissue 
have reached the peripheral blood. However, I do not believe that miR-146a would make a 
good general biomarker for OA in female patients. While it is quite clearly dysregulated in the 
case of OA in both blood, tissues and EVs, it has also been found to be dysregulated in other 
diseases such as cancer (Adami et al., 2019), rheumatoid arthritis (Bae and Lee, 2018), and 
Alzheimer’s disease (Ansari et al., 2019). In the case of cancer, it was found to be 
dramatically overexpressed in primary gastric tumours but it’s expression levels decreased in 
progressed tumours (Adami et al., 2019). While it seems to be a good biomarker to show that 
there are some pathological processes activated in the organism, I do not believe that miR-
146a from SF-EVs could be accurately used as a specific biomarker for OA in female 
patients. 
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2.3.3.2. miR-26b 
miR-26b has been shown to be a potential therapeutic candidate of osteoporosis as it has been 
shown to promote bone marrow stromal cell osteogenesis (H. Hu et al., 2019) and could also 
possibly represent an effective therapeutic strategy for liver fibrosis (L. Li et al., 2019).  As 
well as having therapeutic potential, it has also been shown to play a role in the immune 
response as the overexpression of miR-26b inhibited the replication of vesicular stomatitis 
virus by upregulating interferons (IFNs) (C. Liu et al., 2018) and it has also been implicated 
in cancer. 
miR-26b has been found to be downregulated in patients with OA (Table 5, p. 36)(J. Hu et al., 
2018). It is an miRNA molecule that is capable of suppressing karyopherin subunit alpha 3 
(KPNA3) by targeting its 3’-untranslated region which mediates NF-κB p65 translocation 
(Xuefeng Yin et al., 2017). NF-κB itself is a transcription factor that serves as a mediator of 
inflammatory responses as it induces the expression of pro-inflammatory genes. Deregulation 
of NF-κB activation contributes to the pathogenic processes of inflammatory diseases such as 
OA (T. Liu et al., 2017). 
Similarly, another miR-26b target, KPNA2 (Table 6, p.37) is believed to promote NF-κB 
activation by facilitating P65 nuclear translocation and accelerating OA catabolic events. 
KPNA2 was shown to be upregulated in OA patient’s cartilage and this up-regulation was 
accompanied by the elevated expression of catabolic protein levels, and increased NF-κB P65 
translocation. As well as this, loss of KPNA2 resulted in a decreased translocation of the 
p50/p65 NF-κB complex (R. Tao et al., 2015, p. 2). Therefore, as miR-26b seems to target 
both KPNA2 and KPNA3, it is evident that the miRNA plays a role in OA pathogenesis. 
Furthermore, another predicted target of miR-26b is COL10A1 which is important in 
endochondral bone formation and it is specifically expressed when chondrocytes undergo 
hypertrophy. However, altered expression of COL10A1 is accompanied by abnormal 
chondrocyte hypertrophy which occurs during OA (Gu et al., 2014). It has been suggested 
that during OA, articular chondrocytes undergo differentiation, hypertrophy, and apoptosis 
which mimic the endochondral pathway which is shown by the up-regulation of COL10A1 
and enhanced chondrocyte hypertrophy has been observed in OA cartilage (Lu et al., 2014, p. 
1). Therefore, it is possible that the downregulation of miR-26b leads to the upregulation of 
COL10A1 which, in turn, contributes to OA pathogenesis.  
Another predicted target of miR-26b is prostaglandin-endoperoxide synthase 2 (PTGS2, also 
known as COX-2) which helps with the production of prostaglandin (PG) E2. PGE2 is known 
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to often cause pain and swelling during inflammation and regulate bone formation. Increased 
expression of PTGS2 in the subchondral bone has been shown to be associated with 
spontaneous OA but not traumatic OA (Tu et al., 2019). Therefore, it is possible that the 
upregulation of PTGS2 in the subchondral bone induces OA-associated joint cartilage 
degeneration.  
miR-26b has also been found to be downregulated in male OA patient’s SF-EVs and it is 
quite clear that it could play a role in OA pathogenesis as demonstrated by the genes it is 
predicted to target. However, despite extensive research I could not find any articles that 
linked the presence of miR-26b in blood to OA leading me to believe that such a study has not 
yet been carried out. miR-26b is a very attractive marker for OA but its expression profile 
should also be observed in the peripheral blood to determine if it is a viable biomarker for the 
disease in male OA patients. 
2.3.4. Potential of EVs as biomarkers for OA diagnosis 
There is potential in using EVs as biomarkers for OA diagnosis but before such a thing 
becomes reality, further studies need to be carried out. These possible future studies are 
discussed in the following Conclusions chapter. 
miR-146a is not a good specific biomarker for OA diagnosis in female patients as it has been 
implicated in many diseases and conditions. However, it does have some potential as a 
biomarker to observe the progression of the disease once OA has been diagnosed. As 
mentioned before, miR-146a seems to be upregulated in early OA and downregulated in late 
OA. If the expression patterns of the miRNA molecule could be mapped in detail throughout 
the course of OA progression and it is reflected in EVs, it might be possible to determine the 
stage of the disease using a blood sample.  
However, miR-26b seems to be a viable biomarker for OA in male patients as it is evident 
that this miRNA molecule could play an important role in OA pathogenesis, and it has not 
been implicated in as many diseases as miR-146a. However, the expression patterns of this 
miRNA molecule have not yet been investigated in the human blood or in blood EVs. As 
such, it is difficult to evaluate how good of an OA biomarker this molecule could be.  
Another miRNA molecule that has potential as an OA diagnostic tool is miR-504. This 
miRNA is not mentioned above as there is a lack of information to be found in the context of 
OA. However, it is the only miRNA molecule found to be dysregulated in both male and 
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female OA patients SF-EVs (Kolhe et al., 2017). As such I believe that this miRNA molecule 
does have the potential to be a good biomarker for OA diagnosis. 
However, as it appears that a detailed study on the EV-miRNA profile of the serum, plasma 
and peripheral blood in OA patients has not yet been performed, it is not possible to estimate 
how good these EV-linked miRNAs could be as biomarkers for early-stage OA diagnosis.  
2.4. Conclusion  
OA is a progressive, musculoskeletal disease affecting millions of people worldwide with a 
considerable, long term effect on their quality of life. There is no known cure, but many 
strategies have been devised to help manage the symptoms. However, if a non-invasive early 
diagnostic method could be discovered, the quality of life for those suffering from OA could 
be greatly improved. A novel potential early diagnostic method is comparing the 
transcriptomic profile of OA patient’s SF and blood. The OA transcriptomic profile would 
help to demonstrate the numerous changes that occur in OA tissue, but the SF and blood 
transcriptomic profile have shown no known correlation to that of OA and therefore is not 
usable as a predictive diagnostic tool for now. For this reason, focus has shifted to EVs and 
the cargo they contain, specifically miRNAs. It is possible to compare the general OA 
miRNA profile to SF EV-miRNAs, but it is yet to be determined if these EV-miRNAs get 
transported into the peripheral blood and could be compared to plasma EV-miRNAs. 
However, this is certainly a possibility as EVs are capable of transportation and protecting 
their RNA cargo. miR-146a and miR-26b seem to undoubtedly play a role in the pathogenesis 
of OA but their potential to be used as OA specific biomarkers remains to be determined with, 
seemingly, miR-26b having a higher potential.  
However, publications addressing the transcriptomic profile of EVs in SF and blood from OA 
patients are virtually lacking. Nowadays we have access to high throughput technology 
through which it is possible to carry out more detailed studies. With this kind of technology in 
mind, a potential study that could be done is to take samples from OA (with different stages 
of OA) and non-OA patients and study the transcriptomic profile of their blood, SF and solid 
tissues (cartilage, bone, etc). The focus should be on the general transcriptomic profile as well 
as the EVs and the EV-derived miRNA profile. Furthermore, focus should also be turned to 
the expression patterns of miR-504 as it has already been shown to be dysregulated in male 
and female OA patients. However, during these studies the samples should be divided into 
separate gender groups and analysed separately. Moreover, I feel that studies should be 
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focusing on one EV subtype (exosome, MV or AB) rather than EVs in general for better 
consistency and to prevent the possibility of false conclusions.  
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Ekstratsellulaarsete vesiikulite transkriptoomiline profiil osteoartriiti põdevate 
patsientide sünoviaalvedelikus ja veres 
Kristen Orumaa 
RESÜMEE 
Osteoartriit (OA) on krooniline luu- ja lihaskonna haigus, mis mõjutab suurt osa 
vanemaealisest elanikkonnast. OA ei ole ravitav, küll aga on võimalik kontrollida selle 
haiguse kulgu. Kui oleks võimalik haigust diagnoosida varjases staadiumis, siis oleks 
võimalik tunduvalt rohkem parandada OA põdevate patsientide elukvaliteeti. Praegu 
diagnoositakse OA-d kliiniliselt (sümptomite põhjal), radioloogiliselt (näiteks osteofüütide 
olemasolu põhjal) või sümptomaatiliselt (valu sageduse ja radiograafilise tõendid põhjal). 
Varajast diagnoosi on raske panna, kuna OA algusstaadiumis radioloogilisi sümptomeid veel 
pole, seega võiks varajane diagnoos põhineda näiteks molekulaarsetel markeritel. Üheks 
potentsiaalseks varajase diagnoosi molekulaarseks markeriks võiks olla verest eraldatud 
ekstratsellulaarsetes vesiikulites (EV) leiduvate RNA-de muster. Sellest viidi antud töö 
raames läbi teaduskirjandusel põhinev uuring, mis annaks ülevaate teadmistest EV 
transkriptoomi profiilist OA põdevate patsientide sünoviaalvedelikus (SF) ja veres võrreldes 
OA-d mitte põdevate inimestega. Lisaks püüti leida tõendeid, kas SF EV-de transkriptoomi 
profiil peegeldub veres, mis võimaldaks seda varajase diagnostika tööriistana kasutada. 
Uurimistöö käigus leitud kirjanduse põhjal pole SF ja plasma üldise transkriptoomi profiili 
vahel korrelatsioone leitud, seega ei ole hetkel võimalik plasmat analüüsides teha järeldusi SF 
kohta. Siiski enamik, kui mitte kõik bioloogilised vedelikud sisaldavad EV-sid ja EV-d on 
võimelised nii transportima kui ka kaitsma neis olevaid RNA molekule lagunemise eest. 
Uuringute käigus selgus, et mõned SF-is pärinevate EV-de miRNA-d, mis on seotud OA 
patogeneesiga, on tuvastatud ka üldises SF transkriptoomilises profiilis. Samuti leiti, et vere 
EV-de profiili kohta on tehtud väga vähe uuringuid, mistõttu ei ole võimalik lõplikult öelda, 
kas teatud miRNA-sid saaks kasutada biomarkeritena. EV-de profiili analüüsimine 
diagnostilisel eesmärgil omab suurt potentisaali, kuid et seda rakendada, tuleks antud teemal 
teha hulgaliselt lisauuringuid. OA kudedest tuvastatud miRNA-de hulgast keskenduti töös 
miR-146a-le ja miR-26b-le. Mõlemaid on seostatud erinevate haigustega ning on näidatud, et 
neil on ka teatav terapeutiline potentsiaal. Uurimustöö tulemuste põhjal võib järeldada, et 
kuigi miR-146a ei pruugi olla otstarbeks varajase OA diagnoosimisel, võib see olla kasulik 
OA progresiooni määramisel pärast haiguse diagnoosimist. miR-26b võib siiski osutuda 
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meespatsientide OA potentsiaalseks biomarkeriks, kuid see vajab veel põhjalikumaid 
uuringuid. 
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